



PIPER RUDNICK³ LLP
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 3802-068-27 CIP

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/743,813
Applicant(s): Nagarajan RAMESH et al.
Filing Date: December 24, 2003
For: METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS
TRANSDUCTION IN THE BLADDER EPITHELIUM
Group Art Unit:
Examiner:

SIR:

Attached hereto for filing are the following papers:

**INFORMATION DISCLOSURE STATEMENT
LIST OF RELATED CASES
FORM PTO-1449
13 CITED DOCUMENTS**

Our check in the amount of \$ 0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP

Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Christopher W. Raimund
Registration No.: 47,258

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Nagarajan RAMESH et al.

GROUP ART UNIT:

SERIAL NUMBER: 10/743,813

EXAMINER:



FILED: December 24, 2003

FOR: METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS TRANSDUCTION IN THE BLADDER
EPITHELIUM

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents.

RELATED CASES

- Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- ☐ without fee and within three months of the filing date of the application.
- ☐ without fee and within three months of the date of entry of the U.S. national stage.
- without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- ☐ without fee and with the appropriate certification above.
- ☐ without fee and with a new CPA application.
- ☐ without fee and with a Request for Continued Examination.
- ☐ with fee and before the mailing date of any of a Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- ☐ with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,

PIPER RUDNICK LLP

Steven B. Kelber
Attorney of Record
Registration No. 30,073
Christopher W. Raimund
Registration No. 47,258

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

DOCKET NO.: 3802-068-27 CIP

LIST OF RELATED CASES

Docket Number	Serial or Patent Number	Filing or Issue Date	Status
3802-002-27	10/327,869	December 26, 2002	Pending
3802-030-27 PROV	60/485,115	July 8, 2003	Pending
*3802-068-27 CIP	10/743,813	December 24, 2003	Pending

The cases listed on this Notice of Related Cases include cases which may contain information that is material to patentability. The listing of a case on this Notice should not be taken as an indication or admission that any information contained therein is material. Prior art for each case listed on this Notice may have been cited. **The files corresponding to the listed cases, which are available to the Examiner, may not have not been examined to ascertain the materiality of any prior art therein.** Accordingly, the Examiner is requested to review the file for each case listed on this Notice in order to assess the materiality of such prior art.

*Present application; listed for information.

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-068-27 CIP		SERIAL NO. 10/743,813			
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Nagarajan RAMESH et al.		GROUP ART UNIT			
		FILING DATE December 24, 2003					
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6,165,779	12/2000	ENGLER ET AL.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AB	Derek RAGHAVAN et al., "Biology and Management of Bladder Cancer", N. Engl. J. Med., 322, 16, pp: 1129-38 (1990).					
	AC	Simon F. BREWSTER et al., "Gene Therapy in Urological Oncology: Principles, Strategies and Potential", Eur. Urol. 25, pp: 177-82 (1984).					
	AD	Rei TAKAHASHI et al., "The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells", Natl. Acad. Sci USA 88, pp: 5257-61 (1991).					
	AE	Steven A. ROSENBERG, "The Immunotherapy and Gene Therapy of Cancer", J. Clin. Oncol., 10, pp: 180-99 (1992).					
	AF	C. BASS et al., "Recombinant adenovirus-mediated gene transfer to genitourinary epithelium <i>in vitro</i> and <i>in vivo</i> ", Cancer Gene Therapy 2, 2, pp: 97-104 (1995).					
	AG	Bernard D. MORRIS, JR. et al., "ADENOVIRAL-MEDIATED GENE TRANSFER TO BLADDER <i>IN VIVO</i> ", Urology, 152, pp: 506-50 (1994).					
	AH	Y. BLIXT et al., "Enhancement of intracellular uncoating of adenovirus in HeLa cells in the presence of benzyl alcohol as a membrane fluidizer", Virol., 129, pp: 265-77 (1993).					
	AI	Frederick C. MONSON et al., "INDIGOCARMINE AS A QUANTITATIVE INDICATOR OF UROTHELIAL INTEGRITY", J. Urol., 145, pp: 842-5 (1992).					
	AJ	C.L. PARSONS et al., "BLADDER SURFACE GLYCOSAMINOGLYCANS: AN EPITHELIAL PERMEABILITY BARRIER", J. Urol., 143, pp: 139-42 (1990).					
	AK	D. Robert SIEMENS et al., "EVALUATION OF GENE TRANSFER EFFICIENCY BY VIRAL VECTORS TO MURINE BLADDER EPITHELIUM", J. Urol., 165, pp: 667-71 (2001).					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							